181 related articles for article (PubMed ID: 24314030)
1. Restoration of LRIG1 suppresses bladder cancer cell growth by directly targeting EGFR activity.
Chang L; Shi R; Yang T; Li F; Li G; Guo Y; Lang B; Yang W; Zhuang Q; Xu H
J Exp Clin Cancer Res; 2013 Dec; 32(1):101. PubMed ID: 24314030
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity.
Ye F; Gao Q; Xu T; Zeng L; Ou Y; Mao F; Wang H; He Y; Wang B; Yang Z; Guo D; Lei T
J Neurooncol; 2009 Sep; 94(2):183-94. PubMed ID: 19300910
[TBL] [Abstract][Full Text] [Related]
3. Suppression of bladder cancer cell tumorigenicity in an athymic mouse model by adenoviral vector-mediated transfer of LRIG1.
Li F; Ye ZQ; Guo DS; Yang WM
Oncol Rep; 2011 Aug; 26(2):439-46. PubMed ID: 21567105
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus-mediated LRIG1 expression enhances the chemosensitivity of bladder cancer cells to cisplatin.
Yan Z; Jiang J; Li F; Yang W; Xie G; Zhou C; Xia S; Cheng Y
Oncol Rep; 2015 Apr; 33(4):1791-8. PubMed ID: 25695283
[TBL] [Abstract][Full Text] [Related]
5. [Gene therapy study on bladder cancer with recombinant adenoviral vector carrying LRIG1 gene driven by Survivin promoter].
Yan ZJ; Cheng Y; Jiang JH; Hu JS; Shi XD
Zhonghua Wai Ke Za Zhi; 2012 Aug; 50(8):732-6. PubMed ID: 23157908
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of microRNA-4295 enhances cisplatin-induced gastric cancer cell apoptosis through the EGFR/PI3K/Akt signaling pathway by targeting LRIG1.
Yan R; Li K; Yuan DW; Wang HN; Zhang Y; Dang CX; Zhu K
Int J Oncol; 2018 Dec; 53(6):2566-2578. PubMed ID: 30320337
[TBL] [Abstract][Full Text] [Related]
7. LRIG1 combined with cisplatin enhances bladder cancer lesions via a novel pathway.
Li F; Yang W; Guo D; Hu Z; Xu H; Ye Z
Oncol Rep; 2011 Jun; 25(6):1629-37. PubMed ID: 21431282
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of leucine-rich repeats and immunoglobulin-like domains 1 by microRNA-20a modulates gastric cancer multidrug resistance.
Zhou L; Li X; Zhou F; Jin Z; Chen D; Wang P; Zhang S; Zhuge Y; Shang Y; Zou X
Cancer Sci; 2018 Apr; 109(4):1044-1054. PubMed ID: 29450946
[TBL] [Abstract][Full Text] [Related]
9. [Molecular mechanism of LRIG1 cDNA-induced apoptosis in human glioma cell line H4].
Ye F; Guo DS; Niu HQ; Tao SZ; Ou YB; Lu YP; Lei T
Ai Zheng; 2004 Oct; 23(10):1149-54. PubMed ID: 15473925
[TBL] [Abstract][Full Text] [Related]
10. [Effects of LRIG1 gene on the invasion of bladder cancer in vitro].
Ye ZQ; Yan ZJ; Yang WM; Guo DS
Zhonghua Wai Ke Za Zhi; 2007 Feb; 45(4):258-61. PubMed ID: 17502024
[TBL] [Abstract][Full Text] [Related]
11. LRIG1 inhibits hypoxia-induced vasculogenic mimicry formation via suppression of the EGFR/PI3K/AKT pathway and epithelial-to-mesenchymal transition in human glioma SHG-44 cells.
Zhang X; Song Q; Wei C; Qu J
Cell Stress Chaperones; 2015 Jul; 20(4):631-41. PubMed ID: 25860915
[TBL] [Abstract][Full Text] [Related]
12. LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance.
Billing O; Holmgren Y; Nosek D; Hedman H; Hemmingsson O
Oncogene; 2021 May; 40(21):3707-3718. PubMed ID: 33947959
[TBL] [Abstract][Full Text] [Related]
13. Expression of LRIG1, a Negative Regulator of EGFR, Is Dynamically Altered during Different Stages of Gastric Carcinogenesis.
Yu S; Yang M; Lim KM; Cho Y; Kim H; Lee K; Jeong SH; Coffey RJ; Goldenring JR; Nam KT
Am J Pathol; 2018 Dec; 188(12):2912-2923. PubMed ID: 30248341
[TBL] [Abstract][Full Text] [Related]
14. Over-expression of LRIG1 suppresses biological function of pituitary adenoma via attenuation of PI3K/AKT and Ras/Raf/ERK pathways in vivo and in vitro.
Cheng SQ; Fan HY; Xu X; Gao WW; Lv SG; Ye MH; Wu MJ; Shen XL; Cheng ZJ; Zhu XG; Zhang Y
J Huazhong Univ Sci Technolog Med Sci; 2016 Aug; 36(4):558-563. PubMed ID: 27465333
[TBL] [Abstract][Full Text] [Related]
15. LRIG1 modulates aggressiveness of head and neck cancers by regulating EGFR-MAPK-SPHK1 signaling and extracellular matrix remodeling.
Sheu JJ; Lee CC; Hua CH; Li CI; Lai MT; Lee SC; Cheng J; Chen CM; Chan C; Chao SC; Chen JY; Chang JY; Lee CH
Oncogene; 2014 Mar; 33(11):1375-84. PubMed ID: 23624915
[TBL] [Abstract][Full Text] [Related]
16. Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR.
Torigoe H; Yamamoto H; Sakaguchi M; Youyi C; Namba K; Sato H; Shien K; Soh J; Suzawa K; Tomida S; Tsukuda K; Miyoshi S; Toyooka S
Carcinogenesis; 2018 May; 39(5):719-727. PubMed ID: 29546323
[TBL] [Abstract][Full Text] [Related]
17. Dysregulation and antimetastatic function of circLRIG1 modulated by miR-214-3p/LRIG1 axis in bladder carcinoma.
Cheng S; Li C; Liu L; Liu X; Li M; Zhuo J; Wang J; Zheng W; Wang Z
Biol Direct; 2024 Mar; 19(1):20. PubMed ID: 38454507
[TBL] [Abstract][Full Text] [Related]
18. LRIG1 regulates cadherin-dependent contact inhibition directing epithelial homeostasis and pre-invasive squamous cell carcinoma development.
Lu L; Teixeira VH; Yuan Z; Graham TA; Endesfelder D; Kolluri K; Al-Juffali N; Hamilton N; Nicholson AG; Falzon M; Kschischo M; Swanton C; Wright NA; Carroll B; Watt FM; George JP; Jensen KB; Giangreco A; Janes SM
J Pathol; 2013 Mar; 229(4):608-20. PubMed ID: 23208928
[TBL] [Abstract][Full Text] [Related]
19. Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3).
Rafidi H; Mercado F; Astudillo M; Fry WH; Saldana M; Carraway KL; Sweeney C
J Biol Chem; 2013 Jul; 288(30):21593-605. PubMed ID: 23723069
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation.
Xie R; Yang H; Xiao Q; Mao F; Zhang S; Ye F; Wan F; Wang B; Lei T; Guo D
Oncol Rep; 2013 Jan; 29(1):177-84. PubMed ID: 23124613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]